Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5278279
Max Phase: Preclinical
Molecular Formula: C55H65FN10O9S
Molecular Weight: 1061.25
Associated Items:
ID: ALA5278279
Max Phase: Preclinical
Molecular Formula: C55H65FN10O9S
Molecular Weight: 1061.25
Associated Items:
Canonical SMILES: Cc1ncsc1-c1ccc([C@H](C)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NCCOCCOCCOCCn2cc(CNc3cccc(Cc4c(C)c5ccc(Oc6ncccn6)cc5oc4=O)c3F)nn2)C(C)(C)C)cc1
Standard InChI: InChI=1S/C55H65FN10O9S/c1-34-43-16-15-42(74-54-58-17-8-18-59-54)29-47(43)75-53(70)44(34)27-39-9-7-10-45(48(39)56)60-30-40-31-65(64-63-40)20-22-72-24-26-73-25-23-71-21-19-57-50(55(4,5)6)52(69)66-32-41(67)28-46(66)51(68)62-35(2)37-11-13-38(14-12-37)49-36(3)61-33-76-49/h7-18,29,31,33,35,41,46,50,57,60,67H,19-28,30,32H2,1-6H3,(H,62,68)/t35-,41+,46-,50+/m0/s1
Standard InChI Key: NPFIGSYRYNDRCW-ULINFHPISA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1061.25 | Molecular Weight (Monoisotopic): 1060.4641 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Wang C, Wang H, Zheng C, Li B, Liu Z, Zhang L, Yuan L, Xu P.. (2023) Discovery of Coumarin-Based MEK1/2 PROTAC Effective in Human Cancer Cells., 14 (1.0): [PMID:36655129] [10.1021/acsmedchemlett.2c00446] |
Source(1):